Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future

Y Zhang, H Chen, R Li, K Sterling… - Signal transduction and …, 2023 - nature.com
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

[HTML][HTML] Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer's disease

F Kametani, M Hasegawa - Frontiers in neuroscience, 2018 - frontiersin.org
The so-called amyloid hypothesis, that the accumulation and deposition of oligomeric or
fibrillar amyloid β (Aβ) peptide is the primary cause of Alzheimer's disease (AD), has been …

Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

CJ Mummery, A Börjesson-Hanson, DJ Blackburn… - Nature medicine, 2023 - nature.com
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating
evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT …

The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators

LL Chen, YG Fan, LX Zhao, Q Zhang, ZY Wang - Bioorganic chemistry, 2023 - Elsevier
Abstract Alzheimer's disease (AD), characterized by the β-amyloid protein (Aβ) deposition
and tau hyperphosphorylation, is the most common dementia with uncertain etiology. The …

The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease

M Colom-Cadena, T Spires-Jones, H Zetterberg… - Alzheimer's research & …, 2020 - Springer
Background Synapse damage and loss are fundamental to the pathophysiology of
Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to …

Tau and tauopathies

T Arendt, JT Stieler, M Holzer - Brain research bulletin, 2016 - Elsevier
Most neurodegenerative diseases are characterized by intracellular aggregates of insoluble
proteins. As for the majority of these disorders, aetiology and pathogenesis are only poorly …

Amyloid-β and tau complexity—towards improved biomarkers and targeted therapies

JC Polanco, C Li, LG Bodea… - Nature Reviews …, 2018 - nature.com
Most neurodegenerative diseases are proteinopathies, which are characterized by the
aggregation of misfolded proteins. Although many proteins have an intrinsic propensity to …

Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis

GS Bloom - JAMA neurology, 2014 - jamanetwork.com
The defining features of Alzheimer disease (AD) include conspicuous changes in both brain
histology and behavior. The AD brain is characterized microscopically by the combined …

Interactions of pathological proteins in neurodegenerative diseases

TL Spires-Jones, J Attems, DR Thal - Acta neuropathologica, 2017 - Springer
Neurodegenerative diseases such as Alzheimer's disease (AD), frontotemporal lobar
degeneration (FTD), Lewy body disease (LBD), Parkinson's disease (PD), and amyotrophic …

Tau pathology and neurodegeneration

MG Spillantini, M Goedert - The Lancet Neurology, 2013 - thelancet.com
The pathway leading from soluble and monomeric to hyperphosphorylated, insoluble and
filamentous tau protein is at the centre of many human neurodegenerative diseases …